Literature DB >> 8712028

Charles Bonnet syndrome in leprosy; prevalence and clinical characteristics.

N Adachi1.   

Abstract

Charles Bonnet syndrome (CBS) is diagnosed when a visually impaired patient without any mental disorder develops visual hallucinations. A survey of patients in a National Leprosarium revealed that the point prevalence of CBS in leprosy was 0.4%. This prevalence appears to be high, as few cases with CBS have been reported. The semeiology of visual hallucinations was typical of CBS. However, the clinical features were different from previous reported cases because of the history of leprosy and associated multi-sensory loss. Patients with leprosy appear to be at increased risk for CBS, due to frequent eye complications combined with sensory loss, ageing, and intact intellectual functions.

Entities:  

Mesh:

Year:  1996        PMID: 8712028     DOI: 10.1111/j.1600-0447.1996.tb10648.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  4 in total

1.  Charles Bonnet syndrome and visual acuity--the involvement of dynamic or acute sensory deprivation.

Authors:  Yasuko Shiraishi; Takeshi Terao; Kenji Ibi; Jun Nakamura; Akihiko Tawara
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

2.  Hallucinations in visually impaired individuals: an analysis of the National Comorbidity Survey Replication.

Authors:  Yoshihiro Kinoshita; Masao Tsuchiya; Norito Kawakami; Toshi A Furukawa; David Kingdon
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-26       Impact factor: 4.328

3.  Charles Bonnet's syndrome: not only a condition of the elderly.

Authors:  Heike M Elflein; M Rudy; K Lorenz; K A Ponto; A Scheurich; S Pitz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-25       Impact factor: 3.117

4.  Charles Bonnet Syndrome: Case series.

Authors:  Sonia Maria Dozzi Brucki; Leonel Tadao Takada; Ricardo Nitrini
Journal:  Dement Neuropsychol       Date:  2009 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.